132 - Late Breaker Abstracts

Moderator(s)

• 

  Tara Palmore, MD

  Hospital Epidemiologist
  NIH Clinical Center, Maryland, United States

  I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentations:

• Preliminary Findings from a HIV Self-Testing Program among People Who Use Drugs
  

  Presenting Author: Michelle Rose, MBA – Norton Healthcare

  Co-Author: Laura Guy, BS, CCRC – Norton Healthcare

  Co-Author: Steve Shamblen, PhD – Pacific Institute for Research and Evaluation

  Co-Author: Greg Guest, PhD – Pacific Institute for Research and Evaluation

  Co-Author: Adam Gilbertson, DPhil – Pacific Institute for Research and Evaluation

  Co-Author: Nicholas Peiper, PhD, MPH – University of Louisville
• Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus bacteremia
  

  Presenting Author: Cara Cassino, MD – ContraFect Corporation

  Co-Author: Anita F. Das, PhD – AD Stat Consulting

  Co-Author: Joy Lipka, MS – Lipka Consulting
• The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection
  

  Presenting Author: Laura Hammitt, MD – Johns Hopkins School of Public Health

  Co-Author: Ron Dagan, MD – Ben-Gurion University of the Negev

  Co-Author: Yuan Yuan, PhD – AstraZeneca, Gaithersburg, MD, USA

  Co-Author: Manuel Baca Cots, MD – Quirónsalud Málaga Hospital, Málaga, Spain

  Co-Author: Miroslava Bosheva, MD – University Multiprofile Hospital for Active Treatment Sv. Georgi Medical University, Plovdiv, Bulgaria

  Co-Author: Shabhir A. Mahdi, PhD – University of the Witwatersrand, Johannesburg, South Africa

  Co-Author: William J. Muller, MD, PhD – Northwestern University

  Co-Author: Heather J. Zar, PhD – Red Cross Children's Hospital and SA-MRC Unit on Child & Adolescent Health, University of Cape Town, South Africa

  Co-Author: Dennis Brooks, MD – AstraZeneca, Gaithersburg, MD, USA

  Co-Author: Amy Grenham, MSc – AstraZeneca, Gaithersburg, MD, USA

  Co-Author: Ulrika Wählby Hamrén, PhD – AstraZeneca, Gothenburg, Sweden

  Co-Author: Vaishali S. Mankad, MD – AstraZeneca, Gaithersburg, MD, USA

  Co-Author: Pin Ren, PhD – AstraZeneca

  Co-Author: Therese Takas, BSc – AstraZeneca, Gaithersburg, MD, USA

  Co-Author: Jon Heinrichs, PhD – Sanofi Pasteur, Swiftwater, PA, USA

  Co-Author: Amanda Leach, MRCPCH – AstraZeneca, Gaithersburg, MD, USA

  Co-Author: M. Pamela Griffin, MD – AstraZeneca, Gaithersburg, MD, USA

  Co-Author: Tonya L. Villafana, PhD – AstraZeneca, Gaithersburg, MD, USA
• Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
  

  Presenting Author: Ann R. Falsey, MD – University of Rochester

  Co-Author: Kristi Williams, PhD – Janssen Research and Development, Spring House, PA, USA

  Co-Author: Efi Gymnopoulou, MSc – Janssen Infectious Diseases, Beerse, Antwerpen, Belgium, B-2340

  Co-Author: Stephan A. Bart, MD, CPI – Optimal Research, LLC/Synexus Clinical Research/AES, Woodstock, MD, USA

  Co-Author: John E. Ervin, MD – Alliance for Multispecialty Research - KCM

  Co-Author: Arangassery Rosemary Bastian, PhD – Janssen Infectious Diseases and Vaccines, Leiden, Zuid-Holland, The Netherlands, 2333

  Co-Author: Joris Menten, n/a – Janssen Infectious Diseases, Beerse, Belgium

  Co-Author: Els De Paepe, MSc – Janssen Infectious Diseases, Beerse, Antwerpen, Belgium, B-2340

  Co-Author: Hilde de Boer, MSc – Janssen-Cilag, Tilburg, The Netherlands

  Co-Author: Sjoukje Vandenberghe, n/a – Janssen Infectious Diseases, Beerse, Belgium

  Co-Author: Eric Chan, PhD – Janssen Global Services, LLC, Raritan, NJ, USA

  Co-Author: Jerald Sadoff, MD – Janssen Infectious Diseases and Vaccines, Leiden, Zuid-Holland, The Netherlands, 2333

  Co-Author: Macaya Douoguih, MD, MPH – Janssen Vaccines and Prevention, Leiden, Netherlands

  Co-Author: Benoit Callendret, PhD – Janssen Infectious Diseases and Vaccines, Leiden, Zuid-Holland, The Netherlands, 2333

  Co-Author: Christy Comeaux, MD – Janssen Infectious Diseases and Vaccines, Leiden, Zuid-Holland, The Netherlands, 2333

  Co-Author: Esther Heijnen, MD – Janssen Infectious Diseases and Vaccines, Leiden, Zuid-Holland, The Netherlands, 2333
• SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics
  

  Presenting Author: Timothy J. Straub, MS – Seres Therapeutics

  Co-Author: Liyang Diao, PhD – Seres Therapeutics

  Co-Author: Christopher Ford, PhD – Seres Therapeutics, Inc

  Co-Author: Matthew Sims, MD, PhD – Beaumont Health

  Co-Author: Thomas J. Louie, MD – Cumming School of Medicine, University of Calgary, Calgary, Canada

  Co-Author: Charles Berenson, MD – State University of New York at Buffalo

  Co-Author: Colleen S. Kraft, MD, MSc – Emory University

  Co-Author: Stuart H. Cohen, MD – University of California, Davis

  Co-Author: Alla Paskovaty, PharmD – Seres Therapeutics

  Co-Author: Mary-Jane Lombardo, PhD – Seres Therapeutics, Inc

  Co-Author: Barbara McGovern, MD – Seres Therapeutics, Inc.

  Co-Author: Lisa von Moltke, MD – Seres Therapeutics

  Co-Author: Matt Henn, PhD – Seres Therapeutics, Inc.
• Surveillance Rates of Cefiderocol Heteroresistance Correlate With All-cause Mortality in the APEKS-NP and CREDIBLE-CR Trials
  

  Presenting Author: Jacob E. Choby, PhD – Emory University School of Medicine

  Co-Author: Tugba Ozturk, MS – Emory University

  Co-Author: Sarah W. Satola, PhD – Emory University

  Co-Author: Jesse T. Jacob, MD, MSc – Emory University

  Co-Author: David Weiss, PhD – Emory University School of Medicine
• Immunosequencing of the T-Cell Receptor Repertoire Reveals Signatures Specific for Diagnosis and Characterization of Early Lyme Disease
  

  Co-Author: Julia Greissl, PhD – Microsoft Research

  Co-Author: Mitch Pesesky, PhD – Adaptive Biotechnologies

  Co-Author: Sudeb C. Dalai, MD, PhD – Adaptive Biotechnologies and Stanford University School of Medicine

  Co-Author: Allison W. Rebman, MPH – Johns Hopkins University School of Medicine

  Co-Author: Mark J. Soloski, PhD – Johns Hopkins University School of Medicine

  Co-Author: Elizabeth J. Horn, PhD – Lyme Disease Biobank

  Co-Author: Jennifer N. Dines, MD – Adaptive Biotechnologies

  Co-Author: Rachel M. Gittelman, PhD – Adaptive Biotechnologies

  Co-Author: Thomas M. Snyder, PhD – Adaptive Biotechnologies

  Co-Author: Ryan O. Emerson, PhD – Adaptive Biotechnologies

  Co-Author: Edward Meeds, PhD – Microsoft Research

  Co-Author: Thomas Manley, MD – Adaptive Biotechnologies

  Co-Author: Ian M. Kaplan, PhD – Adaptive Biotechnologies

  Co-Author: Lance Baldo, MD – Adaptive Biotechnologies

  Co-Author: Jonathan M. Carlson, PhD – Microsoft Research

  Co-Author: Harlan S. Robins, PhD – Adaptive Biotechnologies

  Presenting Author: John Aucott, MD – Johns Hopkins University School of Medicine
• Healthcare Utilization for Acute Respiratory Illness by Race/Ethnicity across Ambulatory, Emergency, and Hospital Settings
  

  Presenting Author: Alexandra M. Mellis, PhD – Centers for Disease Control and Prevention

  Co-Author: Matthew Gilmer, MS – GDIT

  Co-Author: Carrie Reed, DSc, MPH – CDC
• Intramuscular therapeutic immunization targeting Rel_Mtb/MIP-3 induces immune signatures associated with better TB control in vivo compared to
  

  Presenting Author: Styliani Karanika, MD – The Johns Hopkins Hospital

  Co-Author: James Gordy, PhD – Johns Hopkins Bloomberg School of Public Health

  Co-Author: Pranita Neupane, MD – Johns Hopkins University School of Medicine

  Co-Author: Richard Markham, MD – Johns Hopkins Bloomberg School of Public Health

  Co-Author: Petros Karakousis, MD – Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine